Use of cSVF Via IV Deployment for Residual Lung Damage After Symptomatic COVID-19 Infection
Conditions: Pulmonary Alveolar Proteinosis; COPD; Idiopathic Pulmonary Fibrosis; Viral Pneumonia; Coronavirus Infection; Interstitial Lung Disease Interventions: Procedure: Microcannula Harvest Adipose Derived tissue stromal vascular fraction (tSVF); Device: Centricyte 1000; Procedure: IV Deployment Of cSVF In Sterile Normal Saline IV Solution; Drug: Liberase Enzyme (Roche); Drug: Sterile Normal Saline for Intravenous Use Sponsors: Healeon Medical Inc; Robert W. Alexander, MD Active, not recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials